Newly inducted into the MEDI Hall of Fame this year, alumna Ann Weber ’82, graduated summa cum laude from Notre Dame with a B.S. in chemistry and earned a Ph.D. in synthetic organic chemistry from Harvard University. She is currently Senior Vice President – Drug Discovery at Kallyope Inc., a New York City-based biotechnology company focused on harnessing the potential of the gut-brain axis.
A collaboration between Jon Camden, Associate Professor of Chemistry and Biochemistry, David Masiello of the University of Washington, and Philip Rack of the University of Tennessee has directly observed hybridized magnetic resonances in plasmonic nanostructures for the first time. The achievement is a critical step toward developing materials that interact with light in unexpected ways and that may someday cloak military equipment throughout the visible spectrum or underlie future PV technology optimized to capture energy from the sun’s infrared rays. Their paper on the work, “STEM/EELS Imaging of Magnetic Hybridization in Symmetric and Symmetry-Broken Plasmon Oligomer Dimers and All-Magnetic Fano Interference,” was published in the American Chemical Society’s Nano Letters.
A full slate of energy-related events is being scheduled for the week of October 2nd as the Center for Sustainable Energy at Notre Dame (ND Energy) prepares for its annual Notre Dame Energy Week. Celebrating its 10th year, the week will feature academic lectures and interactive events with the goal of increasing awareness of energy issues.
Each year, SPARK, a Stanford University initiative that provides the education and mentorship in order to advance research discoveries from the bench to the bedside, hosts a diverse group to participate in a 12-day training course in biotech innovation and entrepreneurship. The program provides an understanding of how biotechnology products, such as medical devices, food science, and general medical science, and companies are created, established, managed, advertised, and funded. Ricardo Romero, graduate student of the Integrated Biomedical Sciences program and researcher in the Harper Cancer Research Institute, had the opportunity to attend the program through the Indiana Clinical and Translational Sciences Institute (Indiana CTSI).
For six College of Science students, summer “break” meant advancing their research skills at MD Anderson Cancer Center in Houston, Texas. The students’ experiences were funded by Notre Dame through the generosity of a donor.
Researchers representing four labs across two colleges at Notre Dame have received a four-year, $1.1 million Research Project Grant (R01) from the National Institute of General Medical Sciences at the National Institutes of Health (NIH). The oldest grant mechanism used by the NIH, the R01 provides support for health-related research and development based on the mission of the NIH.
Consider that a human hair is anywhere from 60,000 to 80,000 nanometers in size. A plasmonic nanoparticle, which is a nanoparticle made of noble metals like gold and silver, at their largest are just 100 nanometers, but pack a big punch.
Collaborative research at Notre Dame has demonstrated that electronic interactions play a significant role in the dimensional crossover of semiconductor nanomaterials. The laboratory of Masaru Kuno, professor of chemistry and biochemistry, and the condensed matter theory group of Boldizsár Jankó, professor of physics, have now shown that a critical length scale marks the transition between a zero-dimensional, quantum dot and a one-dimensional nanowire.
This summer the University of Notre Dame welcomed twelve students to campus to participate in the NSF-funded Research Undergraduate Experience (REU) program in analytical chemistry. The 10-week residential program is open to rising sophomore, junior, and senior undergraduates at four-year colleges, with backgrounds in chemistry, biochemistry, biology, chemical engineering, computer science, and mechanical or electrical engineering. It offers students the opportunity to work with Notre Dame faculty on various research projects aimed at solving analytical problems in the developing world, and “teaches students how to engage with a project at the instrumental and experimental design level.”
Brian Baker, recently named the Rev. John A. Zahm Professor of Structural Biology, has been appointed to the position of chair of the Department of Chemistry and Biochemistry, effective July 1, 2016.
Steven Corcelli, associate professor of chemistry and biochemistry, has been selected as a member of the 2016 Fellows of the American Chemical Society. The American Chemical Society (ACS) announced the news today in Chemical & Engineering News.
As Richard Taylor completes a three-year term as associate vice president for research in June of this year, he will continue his research on drug discovery for rare genetic diseases, like NGLY1 deficiency, when he and other members of the Warren Family Research Center for Drug Discovery and Development move into the building this summer.
At the University of Notre Dame, the Molecular Structure Facility (MSF) analyzes organic or inorganic substances at an atomic level, which allows researchers to learn about the three-dimensional structure and connectivity of the compound they have created. Knowing the molecular make-up of substances oftentimes provides faculty, postdoctoral fellows, and graduate students information about whether or not their substance is actually what was intended or even to see if their research is heading in the right direction.
VeriPAD, a startup created by a multidisciplinary team of City College of New York (CUNY) students and recent graduates in collaboration with University of Notre Dame faculty, was awarded the $25,000 Zahn Innovation Center social impact new venture competition grand prize.
Drugs to treat cancer and Alzheimer’s disease usually target the active sites of specific protein molecules sustaining the disease. Traditional drug design views proteins as rigid 3-D objects with active sites consisting of surface-accessible “pockets” with a specific, well-defined structure. Traditional drug design involves finding small molecules with shapes that fit specifically into this pocket. A new study from University of Notre Dame researchers suggests that there are alternative approaches to targeting these proteins, a significant finding for future clinical applications.